Poor governance creates hidden costs that bleed across clinical programs. Scope drift accumulates silently. Financial leakage happens in budget gaps and contract overages nobody tracks. Rework multiplies in handoff failures and unclear ownership. Leadership fatigue sets in when decisions are questioned and re-made. Delivery slows because priorities shift without clear rationale. Governance breaks at four distinct levels: the board sets strategy but misses execution reality; executives make decisions without full vendor context; operations clash with vendor capabilities; vendors operate without clear accountability. The fix requires governance as a design system: clarity in strategy, explicit priorities, documented assumptions, and agreed conditions before execution begins.

Key Takeaways

Understanding the Four Levels of Governance Breakdown

Governance failures rarely announce themselves. They accumulate in quiet ways. A board approves a vendor selection based on operational assumptions that turn out to be wrong. Executives make decisions about trial timelines without consulting the vendors who will execute them. Operations teams implement processes that vendors cannot support. Vendors operate without clear accountability for decisions they influence.

Each level breaks independently. When all four break together, the result is a program that runs slower, costs more, and delivers less than promised.

Four Levels of Governance Breakdown

The Cost of Silent Scope Drift

Scope drift happens in the gaps between intent and execution. A vendor delivers more than contracted because nobody said no. A trial expands in scope because the decision to expand happened in a meeting without formal approval. Budget shifts because assumptions about effort were never documented. The accumulated effect is a program that costs 20% more and takes 20% longer than planned, but nobody can point to a single decision that caused it.

Building Governance into Strategy

The fix is not more meetings or more approvals. The fix is clarity. Kieran Engels works with sponsors to define strategy with operational precision. What are we building? What are we not building? What are we assuming about vendor capability? What happens if those assumptions break?

Seuss+ helps teams document these decisions and create governance systems that prevent them from being silently eroded. Decision criteria become explicit. Approval pathways become clear. Accountability becomes assigned.

Key Industry Data

The global CRO market reached $79.5 billion in 2023, with the top five players controlling more than 35% of market share. (Source: Grand View Research, IQVIA)

63% of new trial starts now come from emerging biotech companies that often lack internal infrastructure to evaluate CRO capability. (Source: IQVIA)

Between 50% and 60% of all clinical trial activities are outsourced to CROs globally, making selection the single highest impact operational decision. (Source: IQVIA)

A single protocol amendment adds approximately three months and $500,000 or more in unbudgeted costs, often driven by misalignment between sponsor expectations and CRO delivery models. (Source: Tufts CSDD)

Daily trial delays cost sponsors $600,000 to $8 million per day, and mid trial CRO transitions compound those losses significantly. (Source: Tufts CSDD)

Frequently Asked Questions

About the Author

Kieran Engels is CEO and Co-Founder of Seuss+, a strategy and execution partner helping biotech sponsors optimize vendor relationships across clinical development. With more than a decade of experience in vendor governance, risk management, and clinical trial execution, Kieran works with biotech leadership teams to build the oversight systems that protect timelines, budgets, and data integrity. Learn more at seuss.plus.

The post The Hidden Cost of Poor Governance appeared first on Kieran Engels.

Sponsors routinely underinvest in governance because governance looks like overhead. It feels like bureaucracy. The real cost is downstream: scope drift, vendor misalignment, rework, leadership time consumed by decisions that should have been resolved upstream. Every dollar not spent on governance clarity at the beginning generates multiples in hidden cost downstream. This is the pennywise-pound-foolish problem of clinical development. Governance is not bureaucracy. It is the system that prevents waste.

KEY TAKEAWAYS

The conversation happens in almost every sponsor organization. Finance is pushing back on oversight costs. Someone says, “Do we really need this level of governance?” Someone else says, “That feels like overhead. Let’s strip it back and move faster.”

Understanding the Fundamentals

And then eight months into the program, the timeline has slipped. Scope has drifted. The vendor is saying the requirements were unclear. The team is in constant firefighting mode. And the cost overrun is three times what the governance investment would have been.

This is the pennywise-pound-foolish problem of clinical development. Sponsors underinvest in the clarity that prevents problems and then spend multiples managing the problems they could have prevented.

The Real Cost of Misalignment

Let’s be clear about what governance actually is. Governance is not bureaucracy. Governance is the system that prevents the cascade of small misalignments that become big problems. It’s decision rights. It’s clear KPIs. It’s change management. It’s a feedback cadence that lets you catch misalignment early instead of discovering it after months of execution.

The cost of poor governance is not visible. That’s why it gets underfunded. A governance failure doesn’t show up as a line item. It shows up as scope creep. It shows up as a vendor saying they didn’t understand what you needed. It shows up as a timeline extension that wasn’t planned. It shows up as leadership time spent on decisions that should have been resolved upstream.

Building Governance Infrastructure

At Seuss+, Kieran Engels has modeled the hidden cost of governance underinvestment. Sponsors with weak governance structures typically experience 10 to 30 percent scope drift over the course of a clinical development program. That’s not because the science changes. It’s because decision-making authority was never clear. So decisions get made, unmade, and remade as different stakeholders weigh in at different times.

Governance underinvestment also generates vendor misalignment costs. A vendor that wasn’t given clear requirements upfront will misinterpret what they’re supposed to deliver. That misinterpretation doesn’t get caught until they’re already three months into execution. Then you spend six weeks negotiating what was actually supposed to happen. Then they have to rework it. That’s months of delay and cost that could have been prevented by investing in clarity at the kickoff.

The Speed Advantage

The other hidden cost is leadership time. Sponsors with weak governance structures have escalations coming up constantly. A decision needs to be made and no one is clear on who should make it. So it goes to the sponsor’s leadership. A vendor is pushing back on a requirement and no one is clear on what the requirement actually is. So it becomes a leadership conversation. These escalations consume hundreds of hours per year. They distract from strategy. They slow down everything else.

Governance clarity in four areas prevents most of this cascade. Decision rights. Who actually decides things? What decision authority does the sponsor’s leadership have? What authority does the vendor have? What happens if you disagree? If that’s not clear, you’ll spend months discovering it through conflict.

KPI definition. What does success look like? What are you actually measuring? What is the vendor accountable for? If that’s not defined before execution starts, you’ll spend the whole program arguing about whether the vendor is delivering or not.

Change management. How do you handle scope change? Who approves it? What’s the process? If that’s not clear, every change request becomes a negotiation. Scope drift accelerates.

Accountability structure. What’s the feedback cadence? How often do you review performance? What happens if something isn’t on track? If that’s not in place, problems don’t surface until they’re disasters.

Investing in these four things upfront costs time and focus. It’s weeks of conversations with stakeholders about what they actually need and what authority they’re comfortable delegating. It’s negotiation with the vendor about what they’re accountable for. It’s not fast.

But it prevents the alternative. The sponsors who move fastest in clinical development are the ones who got the governance clarity done first. They move faster downstream because decisions are already made. Expectations are aligned. Problems get caught early because there’s a feedback structure in place. Vendors are clear on what they’re accountable for so they deliver on it rather than discovering misalignment months later.

Kieran Engels has seen sponsors try to skip the governance work and move fast. They all end up slower downstream. The governance work doesn’t compress. It just gets moved from the planning phase to the crisis management phase. And in the crisis management phase, it’s more expensive and more costly.

This is also why governance is not a luxury for well-resourced sponsors. It’s a necessity for fast execution. The sponsors with the least budget can least afford to have scope drift, vendor misalignment, and leadership overhead consuming their timeline. They’re the ones who need governance the most.

Governance Investment vs. Downstream Cost Impact

Key Industry Data

70% of clinical trials experience delays, with more than half related to site activation challenges in multi-country programs. (Source: Tufts CSDD)

The EU Clinical Trials Regulation mandates assessment timelines of 50 to 81 days from submission to decision. (Source: EMA)

North America now accounts for only 27% of global trial starts, while Asia accounts for 30%. (Source: Citeline/Statista, 2021)

The Asia Pacific region contributed more than 50% of the 70,000 new clinical trials registered between 2017 and 2021. (Source: Citeline)

Over 452,000 clinical trials are registered globally, with nearly 65,000 actively recruiting as of 2023. (Source: WHO Clinical Trials Observatory)

Frequently Asked Questions

About the Author

Kieran Engels is CEO and Co-Founder of Seuss+, a strategy and execution partner helping biotech sponsors optimize vendor relationships across clinical development. With more than a decade of experience in vendor governance, risk management, and clinical trial execution, Kieran works with biotech leadership teams to build the oversight systems that protect timelines, budgets, and data integrity. Learn more at seuss.plus.

The post Governance Underinvestment,  The Pennywise Problem in Clinical Development appeared first on Kieran Engels.

This article originally appeared as part of The Vendor Edge series on LinkedIn. This is an expanded and updated version for kieranengels.com.

Risk is not something to eliminate. It’s a diagnostic tool. Most clinical development teams respond to risk by building more controls, adding more oversight, and pushing the problem downstream. The teams that actually move fast are the ones who read risk signals early, understand what they mean about governance and vendor readiness, and use that information to make better decisions upstream. When risk is treated as information rather than threat, it becomes one of the most powerful steering tools in a sponsor’s toolkit.

KEY TAKEAWAYS

Let’s be clear about what risk actually is. Risk in clinical development isn’t inherent danger. It’s information. It tells you something about the clarity of your governance, the readiness of your vendors, and the alignment between what you’re asking people to do and what they understand they’re supposed to deliver.

Understanding the Fundamentals

The problem is how sponsors respond to that information. Most clinical development leaders see a risk signal and treat it like a threat. They build another control. They add another approval gate. They escalate the decision. The risk doesn’t go away. It just gets buried deeper, waits longer, and explodes bigger downstream.

Kieran Engels and the team at Seuss+ have spent the last decade watching this pattern repeat. Teams that move fast in clinical development aren’t the ones with the most controls. They’re the ones with the clearest upstream governance. They read risk early, diagnose what it means, and use that diagnosis to reframe the problem.

The Real Cost of Misalignment

Here’s the cognitive shift: Risk is not a problem to solve. It’s a signal to read. When a vendor proposal contradicts itself, that’s not a vendor problem. That’s a governance problem. It means your requirements weren’t clear enough for them to hit. When a timeline is beginning to slip, that’s not a capacity problem. That’s an alignment problem. It means someone isn’t clear on priorities.

The teams that actually succeed understand the difference. They use risk as a diagnostic tool. They ask: What does this signal tell us about clarity, alignment, and readiness? What was supposed to happen that didn’t? What’s the upstream cause?

Building Governance Infrastructure

This isn’t about lower risk. This is about faster decision-making. When you can read risk signals and translate them into specific governance changes, you solve problems before they become crises. You prevent the months of rework that come from discovering misalignment after execution has already begun.

Governance-informed risk reading also changes how you evaluate vendors. Vendor risk is not about whether they’re capable. It’s about whether there’s alignment between what you need and what they actually deliver. A vendor might be technically excellent but structurally misaligned with your decision-making cadence. That’s a risk signal. It tells you something needs to change in how you’re partnering with them.

The Speed Advantage

The truth is that Kieran Engels has watched sponsors spend millions on additional vendor oversight because they couldn’t read the upstream risk signals. The additional controls don’t fix the problem. They slow everything down. What fixes it is going back to the beginning and asking: What was supposed to be clear that wasn’t? What alignment is missing?

This is why governance isn’t overhead. Governance is the system that lets you read risk signals early and respond before they cascade. Every hour you spend getting clear on roles, decision rights, and expectations upstream is an hour that prevents three hours of rework, escalation, and crisis management downstream.

Risk-informed governance also changes how you manage speed. Speed without visibility is panic. Speed with clear governance and honest risk reading is acceleration. The difference is whether you can see the problems coming.

Risk Signals vs. Typical Response vs. Governance-Informed Response

Key Industry Data

An estimated $20 billion in annual R&D spending is wasted due to poor clinical trial management and preventable failures. (Source: Clinical Trials Transformation Initiative)

A single protocol amendment in a Phase III trial adds approximately three months and over $500,000 in unbudgeted direct costs. (Source: Tufts CSDD)

Nearly 60% of all trial protocols require at least one amendment, with one third of those amendments being avoidable. (Source: Tufts CSDD)

39% of Phase III small molecule trials fail to progress to a regulatory application. (Source: Tufts CSDD)

Only 11.8% of drugs entering clinical testing ultimately gain regulatory approval. (Source: Tufts CSDD)

Frequently Asked Questions

About the Author

Kieran Engels is CEO and Co-Founder of Seuss+, a strategy and execution partner helping biotech sponsors optimize vendor relationships across clinical development. With more than a decade of experience in vendor governance, risk management, and clinical trial execution, Kieran works with biotech leadership teams to build the oversight systems that protect timelines, budgets, and data integrity. Learn more at seuss.plus.

The post Risk as a Powerful Tool in Clinical Development appeared first on Kieran Engels.

KEY TAKEAWAYS

The Governance-Performance Link

This is a cornerstone principle: vendor outcomes are governance outputs. Let’s be clear. When a vendor underperforms, your first instinct is to audit their work quality, renegotiate their contract, or replace them entirely. But the root cause is rarely the vendor. It is the system in which they operate. Seuss+ works with biotech teams to diagnose this regularly. When governance is weak, even strong vendors deliver weak results. When governance is strong, adequate vendors deliver adequate results on time.

The truth is: you cannot vendor your way out of a governance problem. If you replace the vendor without fixing governance, the new vendor inherits the same system and produces the same outcome. This is why it is critical to recognize the five warning signs that your governance has degraded.

Sign One: Your Vendor Cannot Answer What Success Looks Like

Ask your vendor to define success for their scope. If the answer is vague, your governance is failing. If they say “meet the timeline” or “deliver quality work,” you have not done the governance work that precedes contracting. Success criteria should be specific, measurable, and aligned to program milestones. They should be written before the statement of work is finalized. If your vendor cannot recite them, they do not have a clear mandate. And you should not expect one vendor to self-create the clarity that your team did not establish.

Sign Two: Your Vendor Operates Unseen Between Governance Forums

Governance is not a quarterly business review. It is a continuous feedback system. If your governance structure only surfaces vendor performance at quarterly reviews, you have 90 days of visibility gap. Issues that should be addressed in week three are discovered in week thirteen. Course correction becomes expensive. Redesign your governance to include more frequent touchpoints: monthly or biweekly forums where vendor performance, blockers, and emerging risks are discussed. The visibility matters more than the formality. Weekly email updates with escalation flags work better than quarterly presentations with no intermediate data.

Sign Three: Your KPIs Do Not Match Your Program Priorities

This is the diagnostic that Kieran Engels sees most often. You set KPIs for a vendor that do not reflect what matters to the program. For example: a CRO KPI focuses on enrollment speed, but your program priority is data quality and subject safety. A database vendor KPI emphasizes delivery dates, but your priority is end-user adoption and training. When KPIs misalign with priorities, vendors optimize for the wrong outcomes. They move fast when you need them to move carefully. They prioritize volume when you need precision. Redesign your KPIs first. Hold them against your program strategy. Then hold the vendor accountable to the KPIs that matter.

Sign Four: Accountability for Decisions Is Distributed or Absent

When a vendor misses a deadline or delivers substandard work, the response should be clear: accountability lands on the vendor, and the sponsor team works to understand why and course-correct. But in many programs, accountability becomes diffuse. “The vendor failed, but we did not have a clear timeline.” “Quality was not there, but we did not have written standards.” “The deliverable did not land right, but we did not specify what right looked like.” When accountability is distributed, no one is responsible. Vendors have no clear mandate. Sponsor teams have no basis for holding them accountable. Redesign your governance to clarify who is accountable for what and what will happen if accountability fails. This is not about blame. It is about clarity.

Sign Five: Your Intent Has Degraded and You Did Not Notice

This is the subtlest warning sign. Programs do not start with unclear intent. They start with clear strategy. But over time, through scope changes, timeline pressure, stakeholder shifts, and competing priorities, the original intent degrades. What you are trying to accomplish becomes less clear. That degradation is invisible until vendor performance starts to drift. A vendor who was aligned to your original intent becomes misaligned as intent fades. This is not the vendor’s failure. It is a governance failure that has metastasized. The fix: reconnect with your original intent. Restate it. Measure it. Share it with your vendors. Make sure they understand not just what they are delivering, but why it matters to the program.

Five Governance Warning Signs: Diagnostic Table

Key Industry Data

FDA warning letters increased 59% year over year in FY2025, with inspection driven letters frequently citing inadequate safety monitoring and reporting. (Source: FDA)

ICH E6(R3), formally adopted by the FDA in September 2025, requires sponsors to maintain risk based oversight of patient safety throughout the trial lifecycle. (Source: FDA/ICH)

Delayed serious adverse event reporting is among the most frequently cited violations in FDA inspections. (Source: FDA enforcement data)

Safety related issues in Phase III trials remain a primary cause of trial failure across therapeutic areas. (Source: Tufts CSDD)

Between 10% and 25% of patients experience an adverse event during clinical encounters, making proactive safety oversight a non negotiable requirement. (Source: WHO patient safety data)

Frequently Asked Questions

About the Author

Kieran Engels is CEO and Co-Founder of Seuss+, a strategy and execution partner helping biotech sponsors optimize vendor relationships across clinical development. With more than a decade of experience in vendor governance, risk management, and clinical trial execution, Kieran works with biotech leadership teams to build the oversight systems that protect timelines, budgets, and data integrity. Learn more at seuss.plus.

The post Five Signs Your Vendor Governance Framework Needs Redesigning appeared first on Kieran Engels.